Utidelone Plus Capecitabine Versus Taxane Plus Capecitabine in HER2-negative Locally Advanced or Metastatic Breast Cancer
It is a phase III trial to explore the efficacy and safety of utidelone plus capecitabine versus taxane plus capecitabine in HER2-negative locally advanced or metastatic breast cancer and the differences of metronomic capecitabine and intermittent capecitabine in combination chemotherapy.
Breast Neoplasms|Locally Advanced or Metastatic Breast Cancer
DRUG: Taxane plus Intermittent Capecitabine|DRUG: Utidelone plus Intermittent Capecitabine|DRUG: Taxane plus Metronomic Capecitabine|DRUG: Utidelone plus Metronomic Capecitabine
Progression Free Survival (PFS), Time from randomization to progression or death (whichever occurred first)., up to 60 months
Objective response rate (ORR), The proportion of patients with a best response of CR or PR, according to RECIST 1.1 criteria., up to 60 months|Time to response (TTR), the time from randomization to the first documentation of disease response (CR or PR)., up to 60 months|Duration of response (DOR), the time from the first evaluation that criteria for CR or PR are met until PD or death is observed, whichever occurs first, calculated only for patients whose best response is evaluated as CR or PR., up to 60 months|Overall survival (OS), Time from randomization to death Time from randomization to death Time from randomization to death Time from randomization to death., up to 60 months
It is a phase III trial to explore the efficacy and safety of utidelone plus capecitabine versus taxane plus capecitabine in HER2-negative locally advanced or metastatic breast cancer and the differences of metronomic capecitabine and intermittent capecitabine in combination chemotherapy.